PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 24 full-time employees. The company went IPO on 2015-10-01. The firm is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Dr. Frank Bedu-Addo is the President of PDS Biotechnology Corp, joining the firm since 2019.
What is the price performance of PDSB stock?
The current price of PDSB is $0.6487, it has increased 2.52% in the last trading day.
What are the primary business themes or industries for PDS Biotechnology Corp?
PDS Biotechnology Corp belongs to Biotechnology industry and the sector is Health Care
What is PDS Biotechnology Corp market cap?
PDS Biotechnology Corp's current market cap is $33.9M
Is PDS Biotechnology Corp a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for PDS Biotechnology Corp, including 2 strong buy, 6 buy, 1 hold, 0 sell, and 2 strong sell